PITTSBURGH, Nov. 8, 2012 /PRNewswire/ -- Mylan Inc. (MYL) today announced that it, along with Famy Care Ltd., has entered into a settlement agreement with Janssen Pharmaceuticals Inc. that will ...

PARSIPPANY, N.J., Feb. 8, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has reached a ...

Lupin Pharmaceuticals announced that it has received FDA approval for Norgestimate and Ethinyl Estradiol Tablets, the generic version of Janssen‘s Ortho Tri-Cyclen Lo tablets. Ortho Tri-Cyclen Lo is a ...

Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo. Watson said it will ...

According to the settlement agreement, Janssen will manufacture and supply an authorized generic version of Ortho Tri-Cyclen Lo to Watson Pharma, which will in turn market and distribute the ...

Shares of pharma major Lupin fell 3.3% after reports of a New Jersey US district court upholding the patent held by a unit of Johnson & Johnson's for a oral contraceptive (OC) drug Ortho Tri-Cyclen Lo ...

Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, which is the generic ...

Jerusalem, Israel, July 17, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated July 7, 2009, the Company and Ortho McNeil Janssen have ...

Mylan Launches Generic Xeloda Mylan announced the launch of Norgestimate and Ethinyl Estradiol Tablets, 0.18mg/0.025mg, 0.215mg/0.025mg, and 0.25mg/0.025mg, the generic version of Janssen's Ortho ...

Pharma firm Lupin Ltd today said it has received US health regulator's approval to sell generic version of oral contraceptive, Ortho Tri-cyclen Lo tablets in the American market. Advisory Alert: It ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated July 1, 2009, Teva and Ortho McNeil Janssen have agreed to cease ...